Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Light Sciences LLC

Division of Light Sciences Oncology Inc.
www.lightsci.com

Latest From TransForm Pharmaceuticals Inc.

Big Pharma's Biggest Drug Delivery Experiment: Johnson & Johnson

J&J has been Big Pharma's most aggressive experimenter with the drug-delivery and formulations world, but its two biggest transactions haven't provided the value J&J had originally hoped for.
BioPharmaceutical Business Strategies

Jumpstart Pays Faster than Discovery: The Moral of the TransForm/J&J Acquisition

With its acquisition of TransForm, J&J has cemented its position as the Big Pharma most interested in the power of jumpstart strategies to create new drugs. The new deal is dwarfed by J&J's 2001 acquisition of Alza, but philosophically the two deals are very much the same--platform technologies that quickly generate relatively low-risk product opportunities for J&J.
BioPharmaceutical Strategy

The Search for Defensible IP in Older Drugs

The jumpstart model reduces drug development risk by starting with existing drugs which are then reformulated or repurposed for new or expanded indications. In every case, the parent drug either already belongs to somebody else or has lost patent protection, or soon will, and is therefore freely available for others to exploit. As such, early competition is a significant risk for any jumpstart product. Devising an IP fence high enough to protect a new product could determine a company's success going forward.
BioPharmaceutical Business Strategies

Novartis Bucks the Trend

While many drug companies now see development as key to boosting productivity, Novartis is investing heavily in its own discovery capacity. A new research head has been hiring hot shots out of biotech firms and academia, assembling new technologies to complement classical skills. Novartis seems to be striving to be mostly self-dependent. Will the bet pay off?
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Ophthalmic
  • Alias(es)
  • Light Sciences Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Light Sciences Oncology Inc.
  • Senior Management
  • Albert Luderer, PhD, Pres. & CEO
    Karen Wetzel, CFO & Dir., Fin. & Admin.
    James Chen, MD, CSO & CTO
    Nick Yeo, VP, Strategic Bus. Dev.
  • Contact Info
  • Light Sciences LLC
    Phone: (425) 369-2800
    34931 SE Douglas St.
    Ste. 200
    Snoqualmie, WA 98065
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register